Skip to main content
TipRanks
Go Ultimate75% OFF

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H (2291) Stock Statistics & Valuation Metrics

1 Followers

Total Valuation

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H has a market cap or net worth of HKD 4.72B. The enterprise value is HKD 2.04B.

Market Cap
HKD 4.72B
Enterprise Value
HKD 2.04B

Share Statistics

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H has 341,776,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
341,776,000
Owned by Insiders
―
Owned by Institutions
0.21%

Financial Efficiency

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 11.75%.

Return on Equity (ROE)
0.12
Return on Assets (ROA)
0.11
Return on Invested Capital (ROIC)
11.75%
Return on Capital Employed (ROCE)
0.14
Revenue Per Employee
1.42M
Profits Per Employee
646.17K
Employee Count
371
Asset Turnover
0.25
Inventory Turnover
0.73

Valuation Ratios

The current PE Ratio of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H is 19.47. LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s PEG ratio is -0.69.

PE Ratio
19.47
PS Ratio
7.77
PB Ratio
1.99
Price to FCF
25.02
Price to Operating Cash Flow
19.09
PEG Ratio
-0.69

Income Statement

In the last 12 months, LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H had revenue of 527.94M and earned 239.73M in profits. Earnings per share was 0.69.

Revenue
527.94M
Gross Profit
446.95M
Operating Income
276.54M
Pretax Income
276.46M
Net Income
239.73M
EBITDA
286.23M
Earnings Per Share (EPS)
0.69

Cash Flow

In the last 12 months, operating cash flow was 208.56M and capital expenditures -51.97M, giving a free cash flow of 156.58M billion.

Operating Cash Flow
208.56M
Free Cash Flow
156.58M
Free Cash Flow per Share
0.45

Dividends & Yields

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H pays an annual dividend of HKD 0.57, resulting in a dividend yield of 4.14%

Dividend Per Share
HKD 0.57
Dividend Yield
4.14%
Payout Ratio
72.43%
Free Cash Flow Yield
4.00%
Earnings Yield
5.08%

Stock Price Statistics

Beta
0.75
52-Week Price Change
-26.65%
50-Day Moving Average
12.91
200-Day Moving Average
12.37
Relative Strength Index (RSI)
49.72
Average Volume (3m)
663.87K

Important Dates

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H upcoming earnings date is Mar 26, 2027, TBA (Not Confirmed).

Last Earnings Date
Aug 21, 2026
Next Earnings Date
Mar 26, 2027
Ex-Dividend Date
May 27, 2026

Financial Position

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H as a current ratio of 23.54, with Debt / Equity ratio of 0.08%

Current Ratio
23.54
Quick Ratio
21.71
Debt to Market Cap
0.00
Net Debt to EBITDA
-4.04
Interest Coverage Ratio
2370.99

Taxes

In the past 12 months, LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H has paid 36.74M in taxes.

Income Tax
36.74M
Effective Tax Rate
0.13

Enterprise Valuation

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H EV to EBITDA ratio is 10.62, with an EV/FCF ratio of 17.12.

EV to Sales
5.32
EV to EBITDA
10.62
EV to Free Cash Flow
17.12
EV to Operating Cash Flow
12.85

Balance Sheet

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H has HKD 1.29B in cash and marketable securities with HKD 1.40M in debt, giving a net cash position of HKD 1.29B billion.

Cash & Marketable Securities
HKD 1.29B
Total Debt
HKD 1.40M
Net Cash
HKD 1.29B
Net Cash Per Share
HKD 3.76
Tangible Book Value Per Share
HKD 4.44

Margins

Gross margin is 82.04%, with operating margin of 44.71%, and net profit margin of 40.12%.

Gross Margin
82.04%
Operating Margin
44.71%
Pretax Margin
46.35%
Net Profit Margin
40.12%
EBITDA Margin
50.07%
EBIT Margin
43.28%

Analyst Forecast

The average price target for LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
-4.20%
EPS Growth Forecast
-25.57%

Scores

Smart Score
6
AI Score
85